Next Investors logo grey

Healthcare and IT lead ASX higher

Published 30-MAR-2020 13:38 P.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The Australian stock market opened on a positive note today, ignoring the negative lead from the US, but arguably playing catch up against the strong run experienced by the Dow Jones last week, as it rallied from less than 19,000 points to pass 22,500 points before closing at 21,636 points.

It was a very different story at home last week with the S&P/ASX 200 (ASX: XJO) trading erratically before finishing at 4842 points, only slightly above the previous Friday’s close.

While the index was up by about 65 points at midday, this followed a period in negative territory not long after the open.

Consequently, these aren’t the signs of a market ready to rebound, understandably so given the constant flow of negative news on the business front, and the fact that initiatives announced on the weekend will only further dampen the stressed business environment, and an Australian economy struggling under the burden of continually dipping into the coffers to assist with social and business packages.

One of the interesting themes to look out for though are telehealth stocks which have come to the forefront after the government put in place several measures to allow consumers access to health professionals via telephones and digital links.

These stocks generally sit outside of the ASX 200, but they have delivered some outstanding gains on Monday morning.

Two of the best performers were HeraMed (HMD +25%) and ResApp Health Limited (RAP +43%) with the latter announcing on Monday morning that it had completed an initial integration of ResAppDx-EU into Coviu’s telehealth platform.

This integration will allow clinicians using Coviu’s platform to perform a remote respiratory assessment using ResApp’s clinically validated and Therapeutic Goods Administration (TGA) approved diagnostic test.

ResApp and Coviu have signed a binding commercial terms sheet and have agreed upon a per test fee for the use of ResAppDx-EU on Coviu’s telehealth platform.

The per-test fee received by ResApp is within the previously targeted range of $5.00 to $10.00 per test.

What is ResApp?

Healthcare stocks lead market higher

Not surprisingly, it was the Healthcare Sector which includes a number of companies with heavy index weighting that helped to provide positive momentum for the broader market.

The S&P/ASX 200 Healthcare Index (ASX: XHJ) surged more than 4.9%, led higher by Ansell (ASX: ANN), a global manufacturer and distributor of health and safety protection solutions.

Aside from the relevance of Ansell’s products in relation to the coronavirus, the company also reaffirmed its 2020 earnings guidance on Monday morning - setting it apart from most other companies which are either withdrawing guidance or lowering their expectations.

While Ansell led the way with a gain of 18%, there were also strong performances from Cochlear (COH +7.3%) and diagnostics groups, Pro Medicus (PME +8%) and Sonic Healthcare (SHL +4.3%).

The latter two companies should benefit from an uptick in medical tests.

Information Technology was another strong performer with the XIJ index up nearly 3%.

It would appear that investors are targeting companies with particularly strong intellectual property that should remain resilient despite challenging conditions.

These included Altium (ALU +5.2%), Appen (APX +5%) and NEXTDC (NXT +6.4%), with the latter having reaffirmed its fiscal 2020 revenue and underlying earnings guidance in mid-March.

Importantly, the majority of NEXTDC’s income is derived from contracted and recurring revenues with counterparties carrying investment-grade credit ratings.

Property -related stocks cop a hit

Given the pressure on savings and disposable income, it isn’t surprising to see property related stocks out of favour.

The REIT Index (XPJ) was down more than 1% and the S&P/ASX 200 Materials Index (XMJ), home to both mining companies and building materials stocks was down 1.7%.

It was a mixed bag across the building materials sector with BlueScope Steel (BSL) up 3%, while Boral (BLD) and Brickworks (BKW) were down 4.5% and 1.4% respectively.

Elsewhere, Fletcher Building (FBU) was a casualty as it lost 3.4% and CSR (CFSR) was also in the red, down 1%.

With more shops closing it wouldn’t have been surprising to see the S&P/ASX 200 Consumer Discretionary Index (XDJ) succumb to further pressure.

However, the index was up 2.7% and there were strong performances from takeaway foods chain Collins Foods (CKF +4.2%), travel group Corporate Travel Ltd (CTD +4.6%) and provider of gaming equipment, Aristocrat Leisure (ALL +4.1%).

In the financial sector, the big banks were all in the black, pushing the index 2% higher.

Across the four big banks, the Commonwealth led the way with a gain of 3.1%, followed by ANZ (+1.2%), NAB (+0.6%) and Westpac (+2.5%).

Insurance Australia Group (IAG +5%) was the best performer in the sector.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.